BR0016145A - Clones infecciosos - Google Patents

Clones infecciosos

Info

Publication number
BR0016145A
BR0016145A BR0016145-4A BR0016145A BR0016145A BR 0016145 A BR0016145 A BR 0016145A BR 0016145 A BR0016145 A BR 0016145A BR 0016145 A BR0016145 A BR 0016145A
Authority
BR
Brazil
Prior art keywords
rna
dna
grna
virus
structural
Prior art date
Application number
BR0016145-4A
Other languages
English (en)
Inventor
Luis Enjuanes Sanchez
Original Assignee
Consejo Superior Investigacion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8310818&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0016145(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Consejo Superior Investigacion filed Critical Consejo Superior Investigacion
Publication of BR0016145A publication Critical patent/BR0016145A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A61K39/225—Porcine transmissible gastroenteritis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20041—Use of virus, viral particle or viral elements as a vector
    • C12N2770/20043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20061—Methods of inactivation or attenuation
    • C12N2770/20062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"CLONES INFECCIOSOS". A presente invenção refere-se a processos de preparação de um DNA que compreende as etapas, em que (a) um DNA que compreende uma cópia de comprimento completo do RNA genómico (gRNA) de um vírus de RNA; ou (b) um DNA que compreende um ou vários fragmentos de um gRNA de um vírus RNA, cujos fragmentos codificam uma RNA polimerase dependente de RNA e pelo menos uma proteína estrutural ou não-estrutural; ou (c) um DNA que possui uma homologia de pelo menos 60% com as seq³ências de (a) ou (b); é clonado em um cromossomo artificial de bactéria (BAC). Adicionalmente, são fornecidos DNAS, que compreendem seq³ências derivadas do RNA genómico (gRNA) de um coronavírus cujas seq³ências possuem uma homologia de pelo menos 60% com a seq³ência natural do vírus e codificam uma RNA polimerase dependente de RNA e pelo menos uma proteína estrutural ou não-estrutural, em que um fragmento do dito DNA é capaz de ser transcrito em RNA cujo RNA pode ser montado em um vírion. Ainda, é divulgado o uso destes ácidos nucléicos para a preparação de RNA viral ou de vírions assim como de preparações farmacêuticas que compreendem DNAS, RNAs virais ou vírions.
BR0016145-4A 1999-12-03 2000-11-30 Clones infecciosos BR0016145A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES009902673A ES2170622B1 (es) 1999-12-03 1999-12-03 Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
PCT/EP2000/012063 WO2001039797A2 (en) 1999-12-03 2000-11-30 Artificial chromosome constructs containing nucleic acid sequences capable of directing the formation of a recombinant rna-virus

Publications (1)

Publication Number Publication Date
BR0016145A true BR0016145A (pt) 2002-08-13

Family

ID=8310818

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0016145-4A BR0016145A (pt) 1999-12-03 2000-11-30 Clones infecciosos

Country Status (27)

Country Link
US (4) US7445928B2 (pt)
EP (2) EP1234024B2 (pt)
JP (1) JP4637432B2 (pt)
KR (1) KR100755814B1 (pt)
CN (3) CN100402643C (pt)
AR (1) AR027893A1 (pt)
AT (1) ATE267246T1 (pt)
AU (2) AU785081B2 (pt)
BR (1) BR0016145A (pt)
CA (1) CA2393325A1 (pt)
CZ (1) CZ302785B6 (pt)
DE (1) DE60010921T3 (pt)
DK (1) DK1234024T4 (pt)
ES (2) ES2170622B1 (pt)
HU (1) HU228205B1 (pt)
IL (2) IL149859A0 (pt)
MX (1) MXPA02005525A (pt)
NO (1) NO331812B1 (pt)
NZ (1) NZ518990A (pt)
PL (1) PL206816B1 (pt)
PT (1) PT1234024E (pt)
RS (1) RS50372B (pt)
SI (1) SI1234024T2 (pt)
SK (1) SK7612002A3 (pt)
TR (1) TR200401186T4 (pt)
WO (1) WO2001039797A2 (pt)
ZA (1) ZA200203560B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2170622B1 (es) 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
AU2002311668B2 (en) * 2001-05-17 2007-10-04 Stichting Voor De Technische Wetenschappen Corona-virus-like particles comprising functionally deleted genomes
US7556957B2 (en) 2001-05-17 2009-07-07 Stichting Voor De Technische Wetenschappen Coronavirus-like particles comprising functionally deleted genomes
US7906311B2 (en) 2002-03-20 2011-03-15 Merial Limited Cotton rat lung cells for virus culture
US7371837B2 (en) * 2004-07-21 2008-05-13 The University Of Hong Kong Human virus causing respiratory tract infection and uses thereof
EP1619246A1 (en) * 2004-07-23 2006-01-25 Université de la Méditerranée, Aix-Marseille II RNA dependent RNA polymerases from coronavirus and their use in molecular biology and drug screening
EP2295590A1 (en) 2004-09-03 2011-03-16 Consejo Superior De Investigaciones Cientificas Nucleic acid sequences encoding proteins capable of associating into a virus-like particle
EP1632247A1 (en) * 2004-09-03 2006-03-08 Consejo Superior De Investigaciones Cientificas Nucleic acid sequences encoding FMDV proteins capable of associating into a virus-like particle
WO2006047603A2 (en) 2004-10-22 2006-05-04 Revivicor, Inc. Ungulates with genetically modified immune systems
EP1792996A1 (en) 2005-12-01 2007-06-06 Consejo Superior de Investigaciones Cientificas Nucleic acid sequences encoding vaccines against Porcine reproductive and respiratory syndrome virus (PRRSV)
JP2007312649A (ja) * 2006-05-24 2007-12-06 Japan Health Science Foundation 再構築された感染性レトロウイルスゲノムクローンｄｎａ及びそれを含む微生物ならびにそれらの製造方法
WO2010051288A1 (en) 2008-10-27 2010-05-06 Revivicor, Inc. Immunocompromised ungulates
FR2947839A1 (fr) * 2009-07-09 2011-01-14 Centre Nat Rech Scient Nouveaux agents antibacteriens
EP2681232A1 (en) 2011-03-02 2014-01-08 Intervet International B.V. Infectious bronchitis virus (ibv) spike protein as subunit vaccine
GB201307528D0 (en) * 2013-04-26 2013-06-12 Univ Leuven Kath Bacterial artificial chromosomes
JP2017515508A (ja) * 2014-05-16 2017-06-15 イエール ユニバーシティ 慢性ｂ型肝炎ウイルス（ｈｂｖ）感染症を予防または処置するためのウイルス様ベシクル（ｖｌｖ）ベースのワクチン
WO2015175382A1 (en) * 2014-05-16 2015-11-19 Yale University Evolution of high-titer virus-like vesicles for vaccine applications
EP3198008B1 (en) 2014-09-22 2019-05-29 Regents of the University of Minnesota Pichinde virus reverse genetics system and methods of use
GB201603374D0 (en) 2016-02-26 2016-04-13 Ucl Business Plc Packaging cell
CN107190022B (zh) * 2017-06-28 2020-10-30 浙江大学 一种快速构建禽传染性支气管炎病毒反向遗传株的方法
WO2019204654A1 (en) * 2018-04-18 2019-10-24 Utah State University Compositions and methods for zika virus characterization and vaccine development
KR102119875B1 (ko) * 2019-03-19 2020-06-05 한국화학연구원 한국형 중동호흡기증후군 코로나바이러스 감염성 변이 유전자 및 이의 용도
CN110468113A (zh) * 2019-08-07 2019-11-19 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 重组修饰的猪传染性胃肠炎病毒强毒株及其应用
CN110656120A (zh) * 2019-10-16 2020-01-07 中国医学科学院医学生物学研究所 一种乙脑病毒sa14-14-2的克隆方法及应用
CN111662885A (zh) * 2020-06-22 2020-09-15 扬州大学 两株基因组高度同源猪繁殖与呼吸综合征病毒强弱毒株感染性克隆构建、拯救与应用
CN112852873B (zh) * 2021-02-04 2023-03-24 华中农业大学 一种猪δ冠状病毒感染性克隆质粒的构建方法
CN115094142B (zh) * 2022-07-19 2024-05-28 中国医学科学院肿瘤医院 用于诊断肺肠型腺癌的甲基化标志物

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
US4946787A (en) * 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5545412A (en) * 1985-01-07 1996-08-13 Syntex (U.S.A.) Inc. N-[1, (1-1)-dialkyloxy]-and N-[1, (1-1)-dialkenyloxy]-alk-1-yl-n,n,n-tetrasubstituted ammonium lipids and uses therefor
US5106733A (en) * 1987-06-25 1992-04-21 Immunex Corporation Bovine granulocyte-macrophage colony stimulating factor
CA2045129A1 (en) 1989-02-01 1990-08-02 Alfred I. Geller Herpes simplex virus type i expression vector
US5811103A (en) * 1989-03-19 1998-09-22 Akzo Nobel N.V. Hog cholera virus vaccine and diagnostic
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
CA2039921A1 (en) 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
JP3602530B2 (ja) * 1991-03-07 2004-12-15 ヴァイロジェネティクス コーポレイション 遺伝子操作したワクチン菌株
ES2026827A6 (es) * 1991-03-26 1992-05-01 Ercros Sa Procedimiento para la produccion de una vacuna subunidad contra el parvovirus porcino.
US5382425A (en) * 1992-01-13 1995-01-17 Syntro Corporation Recombinant swinepox virus
US6033904A (en) * 1992-01-13 2000-03-07 Syntro Corporation Recombinant swinepox virus
US5658724A (en) 1992-07-31 1997-08-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains deficient for the essential immediate early genes ICP4 and ICP27 and methods for their production, growth and use
SK98695A3 (en) * 1993-02-08 1996-11-06 Bayer Ag Process for growing porcine reproductive and respiratory syndrome virus and its use in vaccines
US5910488A (en) * 1993-06-07 1999-06-08 Vical Incorporated Plasmids suitable for gene therapy
US20020146392A1 (en) 1993-06-24 2002-10-10 Frank L. Graham Helper dependent adenovirus vectors based on site-specific recombinases
WO1995003400A1 (en) * 1993-07-23 1995-02-02 Johns Hopkins University School Of Medicine Recombinationally targeted cloning in yeast artificial chromosomes
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
AU710504B2 (en) * 1994-03-15 1999-09-23 Brown University Research Foundation Polymeric gene delivery system
ES2243937T3 (es) * 1994-04-29 2005-12-01 Baxter Healthcare S.A. Poxvirus recombinados en regiones esenciales con la ayuda de polinucleotidos extraños.
DK53595A (da) * 1994-05-13 1995-11-14 Iberica Cyanamid Rekombinante PRRSV-proteiner, diagnostiske kits og vaccine indeholdende sådanne rekombinante PRRSV-proteiner
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
WO1996015779A1 (en) 1994-11-21 1996-05-30 The Trustees Of Columbia University In The City Of New York Unique associated kaposi's sarcoma virus sequences and uses thereof
US5719131A (en) * 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
US6287557B1 (en) 1995-02-21 2001-09-11 Cantab Pharmaceuticals Research Limited Methods of gene therapy using herpes viral vectors expressing GM-CSF
US6043232A (en) * 1997-07-23 2000-03-28 Nitromed, Inc. Nitroso esters of beta-oxo-amides and aryl propionic acid derivatives of non-steroidal antiinflammatory drugs
US6019980A (en) * 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US5705385A (en) * 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5820869A (en) * 1995-06-07 1998-10-13 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
US5851826A (en) 1995-07-26 1998-12-22 Children's Medical Center Corporation Helper virus-free herpesvirus vector packaging system
US5795872A (en) * 1995-09-19 1998-08-18 Pharmadigm, Inc. DNA construct for immunization
US6133243A (en) 1996-02-22 2000-10-17 Onyx Pharmaceuticals, Inc. Liposomal-viral DNA complexes for treating disease
ES2109189B1 (es) * 1996-03-14 1998-05-16 Iberica Cyanamid Vectores basados en genomas virales defectivos recombinantes y su empleo en la formulacion de vacunas.
FR2751224B1 (fr) * 1996-07-19 1998-11-20 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs
US5990091A (en) * 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US6004777A (en) * 1997-03-12 1999-12-21 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
DE19733364A1 (de) * 1997-08-01 1999-02-04 Koszinowski Ulrich H Prof Verfahren zur Klonierung eines großen Virusgenoms
US6391314B1 (en) * 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
US7211379B2 (en) * 1997-10-03 2007-05-01 Merial Sas Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2
UA78180C2 (uk) * 1997-10-03 2007-03-15 Меріаль Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
FR2781159B1 (fr) * 1998-07-06 2000-10-06 Merial Sas Vaccin circovirus et parvovirus porcin
US6517843B1 (en) * 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
US6165493A (en) * 1997-10-22 2000-12-26 New York Blood Center, Inc. "Methods and compositions for decreasing the frequency of HIV, herpesvirus and sexually transmitted bacterial infections"
US20040062775A1 (en) * 1997-12-05 2004-04-01 Agence Francaise De Securite Sanitaire Des Aliments Circovirus sequences associated with piglet weight loss disease (PWD)
FR2772047B1 (fr) * 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
KR100879650B1 (ko) * 1997-12-11 2009-01-20 유니버시티 오브 사스카췌완 돼지로부터의 이유후 다기관계작용성 소모 증후군 바이러스
US6277621B1 (en) * 1998-02-26 2001-08-21 Medigene, Inc. Artificial chromosome constructs containing foreign nucleic acid sequences
EP1064024A4 (en) * 1998-03-13 2005-04-06 Univ Georgia Res Found VACCINES AGAINST CIRCOVIRUS INFECTIONS
US6497883B1 (en) * 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
ES2170622B1 (es) 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
IL149704A0 (en) 1999-12-14 2002-11-10 Novartis Ag Bovine immunodeficiency virus (biv) based vectors
AU2001264802A1 (en) 2000-05-21 2001-12-03 University Of North Carolina At Chapel Hill Assembly of large viral genomes and chromosomes from subclones
DE10044648A1 (de) * 2000-09-08 2002-03-21 Aventis Behring Gmbh Verfahren zur Vermehrung oder zur Entfernung von Cirocoviren aus biologischem Material
MY146518A (en) * 2001-03-27 2012-08-15 Univ Saskatchewan Methods to culture circovirus.

Also Published As

Publication number Publication date
EP1437400A3 (en) 2004-10-20
AR027893A1 (es) 2003-04-16
IL149859A0 (en) 2002-11-10
SK7612002A3 (en) 2002-11-06
YU37502A (sh) 2005-11-28
AU3005101A (en) 2001-06-12
US20030148325A1 (en) 2003-08-07
WO2001039797A3 (en) 2002-01-24
ES2218276T5 (es) 2010-10-07
HU228205B1 (en) 2013-01-28
HUP0203305A2 (hu) 2003-01-28
CZ20021882A3 (cs) 2002-11-13
JP4637432B2 (ja) 2011-02-23
PL206816B1 (pl) 2010-09-30
CA2393325A1 (en) 2001-06-07
ZA200203560B (en) 2003-03-26
US20040086846A1 (en) 2004-05-06
CN1616670A (zh) 2005-05-18
CZ302785B6 (cs) 2011-11-09
CN1402780A (zh) 2003-03-12
EP1437400A2 (en) 2004-07-14
ATE267246T1 (de) 2004-06-15
IL149859A (en) 2009-07-20
NO20022419L (no) 2002-07-30
AU785081B2 (en) 2006-09-14
SI1234024T2 (sl) 2010-10-29
NZ518990A (en) 2004-03-26
US20110142879A1 (en) 2011-06-16
DK1234024T3 (da) 2004-09-13
TR200401186T4 (tr) 2004-07-21
SI1234024T1 (en) 2004-08-31
ES2170622B1 (es) 2004-05-16
CN1872994A (zh) 2006-12-06
MXPA02005525A (es) 2004-09-10
US7445928B2 (en) 2008-11-04
PT1234024E (pt) 2004-08-31
KR20020060251A (ko) 2002-07-16
AU2006203327A1 (en) 2006-08-31
DE60010921T2 (de) 2006-05-11
US7368557B2 (en) 2008-05-06
DE60010921T3 (de) 2011-01-05
EP1234024B1 (en) 2004-05-19
KR100755814B1 (ko) 2007-09-07
CN100402643C (zh) 2008-07-16
ES2218276T3 (es) 2004-11-16
EP1234024B2 (en) 2010-06-16
HUP0203305A3 (en) 2004-07-28
AU2006203327B2 (en) 2009-09-10
PL356390A1 (en) 2004-06-28
RS50372B (sr) 2009-11-10
US20100167352A1 (en) 2010-07-01
DK1234024T4 (da) 2010-10-11
DE60010921D1 (de) 2004-06-24
JP2003515335A (ja) 2003-05-07
ES2170622A1 (es) 2002-08-01
EP1234024A2 (en) 2002-08-28
WO2001039797A2 (en) 2001-06-07
NO20022419D0 (no) 2002-05-22
NO331812B1 (no) 2012-04-10

Similar Documents

Publication Publication Date Title
BR0016145A (pt) Clones infecciosos
Van Vliet et al. Discontinuous and non‐discontinuous subgenomic RNA transcription in a nidovirus
Honda et al. A phylogenetically conserved stem-loop structure at the 5′ border of the internal ribosome entry site of hepatitis C virus is required for cap-independent viral translation
Katze et al. Metabolism and expression of RNA polymerase II transcripts in influenza virus-infected cells
DK605987D0 (da) Bestemte dna-sekvenser afledt af et papillomavirus-genom, deres anvendelse til in vitro diagnoseformaal og fremstilling af antigeniske praeparater
HUP9903829A1 (hu) RNS-vírusok fertőző klónjai,belőlük kifejlesztett vakcinák és diagnosztikai eljárások
BRPI9913721B8 (pt) molécula de rna recombinante, vírus quimérico, método para produzir um vírus quimérico de rna de fita negativa, e, formulação de vacina
MX9700817A (es) Secuencia viral de nucleotidos de "vr-2332" y metodos de uso.
DE69842165D1 (de) Herstellung attenuierter parainfluenza-virus impfstoffe aus klonierten nukleotidsequenzen
WO2005014806A3 (en) Conserved hbv and hcv sequences useful for gene silencing
Budzilowicz et al. In vitro synthesis of two polypeptides from a nonstructural gene of coronavirus mouse hepatitis virus strain A59
Ihara et al. Analyses of the mRNA transcription processes of Punta Toro phlebovirus (Bunyaviridae)
Buck Replication of double-stranded RNA in particles of Penicillium stoloniferum virus S
Bridgen et al. Further analysis of the genome of porcine epidemic diarrhoea virus
Kusov et al. RNA-protein interactions at the 3'end of the hepatitis A virus RNA
Fukushi et al. Specific interaction of a 25-kilodalton cellular protein, a 40S ribosomal subunit protein, with the internal ribosome entry site of hepatitis C virus genome
Ritchie et al. Identification and characterisation of the genomic segment 7 of the infectious salmon anaemia virus genome
Smits et al. Torovirus non-discontinuous transcription: mutational analysis of a subgenomic mRNA promoter
Haas et al. Analysis of the H gene, the central untranslated region and the proximal coding part of the F gene of wild-type and vaccine canine distemper viruses
Reichmann et al. Rhabdovirus defective particles: Origin and genome assignments
CN100554428C (zh) 增强有用基因表达的核酸序列和方法
TH63069A (th) โคลนก่อการติดเชื้อ
WO2002061048A3 (en) In vitro system for replication of rna-dependent rna polymerase (rdrp) viruses
Inglis et al. An influenza virus gene encoding two different proteins
Herold et al. Characterization of the human coronavirus 229E (HCV 229E) gene 1

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT. CL.: A61K 39/00.

Ipc: C12N 7/04 (2010.01), C12N 15/50 (2010.01), C12N 1/

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 14A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2282 DE 30/09/2014.